An observational study in Venous Congestion and Organ Dysfunction Syndrome, sponsored by Centre Hospitalier Universitaire Dijon. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Centre Hospitalier Universitaire Dijon · Observational
Among 17 studies in Hyperemia with a site in France — 9 open to participants now, 9 under way, none of them phase 3. Hyperemia · France.
Among the 17 studies in Hyperemia with a site in France, this one is the 2nd largest by enrollment of the 12 observational ones, is one of 2 that started in 2020, is one of 12 observational ones, and was the 5th registered.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
This study's enrollment of 185 is above the median of 100 across 46 observational studies indexed under Hyperemia.
Browse Hyperemia studies →9 of the 17 studies in Hyperemia with a site in France are open now, in 2 countries. Each count lists the studies.
Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →17 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2020.
Median enrollment 60 across the 5 interventional studies, 82 across the 12 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
None of the 17 has an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.
Centre Hospitalier Universitaire Dijon has 1 study filed under Hyperemia — fewer than ten, so there is no comparison to draw.
5 of the studies in Hyperemia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07438015Centre Hospitalier Universitaire de BesanconVEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit | 2027-03-12 |
| NCT06251713Hospices Civils de LyonFluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery | 2027-07 |
| NCT06958809Hospital Ambroise Paré ParisEvolution of Tissue Perfusion and Venous Congestion Markers in Fluid-Responsive Septic Shock Patients | 2027-07-01 |
| NCT07077772Centre Hospitalier Universitaire, AmiensNatriuresis-guided Depletion After Cardiac Surgery | 2027-10 |
| NCT07452952University Hospital, AngersRelationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distress Syndrome. | 2027-11-01 |
Among the 17 studies in Hyperemia with a site in France, from their registry updates:
Venous congestion, which is a phenomenon described in cardiology and post-operative cardiac surgery, is responsible for an increase in morbidity and mortality.
Indeed, it can lead to kidney failure, liver failure, prolonged ileus, scarring complications, and neurological disorders. Clinical and ultrasound indications have been described to diagnose this condition.
To date, this phenomenon is poorly known and not described in intensive care patients outside the cardiac context. However, intensive care patients can present the risk factors associated with the occurrence of congestion: acute cardiac failure, significant water-salt overload, and/or fluid distribution anomalies. Thus, observational studies have found an association between the input-output balance, the quantity of salt-water intake, the presence of right heart dysfunction and the occurrence of acute kidney failure, digestive disorders, hypoxemia and a prolonged stay in intensive care. The presence of a congestive condition is medically treatable since diuretic decongestion is associated with improved cardiac outcomes.
It is therefore necessary, in an intensive care context, to be able to define and diagnose this state of venous congestion, to study its prevalence, and to confirm the existence of a link with organ failure in order to pave the way to known adapted treatment options.
patient admitted to intensive care for less than 24 hours
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient admitted to intensive care for less than 24 hours.
Other: collection of biological parameters · Other: collection of echographic parameters · Other: collection of clinical parameters
haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
the presence of venous congestion
Time frame: From date of inclusion until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 28 day
Ran from Oct 2020 to primary completion in Oct 2022, 24 months.
Of 28 observational studies under Hyperemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Dijon →